Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL)

Market Closed
13 Jun, 20:00
NYSE NYSE
$
149. 45
-2.44
-1.61%
$
7.42B Market Cap
- P/E Ratio
0.4% Div Yield
699,400 Volume
- Eps
$ 151.89
Previous Close
Day Range
148.62 152.64
Year Range
91.86 254.15

Summary

CRL closed today lower at $149.45, a decrease of 1.61% from yesterday's close, completing a monthly increase of 25.19% or $30.07. Over the past 12 months, CRL stock lost -20.05%.
CRL is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2025, exceeded the consensus estimates by 0.27%. On average, the company has surpassed earnings expectations by 0.19%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track CRL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

CRL Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 week ago
Charles River Stock May Gain From Extended CHDI Research Deal on HD

Charles River Stock May Gain From Extended CHDI Research Deal on HD

CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.

Zacks | 1 week ago
Should You Continue to Hold Charles River Stock in Your Portfolio?

Should You Continue to Hold Charles River Stock in Your Portfolio?

CRL stays on investors' radars due to the strength of partnerships and segmental prospects.

Zacks | 3 weeks ago

Charles River Laboratories International, Inc. Dividends

CRL is not paying dividends to its shareholders.

Charles River Laboratories International, Inc. Earnings

7 May 2025 Date
2.07
Cons. EPS
2.34
EPS
12 Feb 2025 Date
2.53
Cons. EPS
2.66
EPS
6 Nov 2024 Date
2.43
Cons. EPS
2.59
EPS
7 Aug 2024 Date
2.39
Cons. EPS
2.8
EPS
9 May 2024 Date
2.07
Cons. EPS
2.27
EPS
CRL is not paying dividends to its shareholders.
7 May 2025 Date
2.07
Cons. EPS
2.34
EPS
12 Feb 2025 Date
2.53
Cons. EPS
2.66
EPS
6 Nov 2024 Date
2.43
Cons. EPS
2.59
EPS
7 Aug 2024 Date
2.39
Cons. EPS
2.8
EPS
9 May 2024 Date
2.07
Cons. EPS
2.27
EPS

Charles River Laboratories International, Inc. (CRL) FAQ

What is the stock price today?

The current price is $149.45.

On which exchange is it traded?

Charles River Laboratories International, Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is CRL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 7.42B.

Has Charles River Laboratories International, Inc. ever had a stock split?

No, there has never been a stock split.

Charles River Laboratories International, Inc. Profile

Medical - Diagnostics & Research Industry
Healthcare Sector
Mr. James C. Foster J.D. CEO
NYSE Exchange
159864107 Cusip
US Country
18,700 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Charles River Laboratories International, Inc. stands as a pivotal organization within the pharmaceutical industry, providing a comprehensive suite of services encompassing drug discovery, non-clinical development, and safety testing. With a global footprint that extends across the United States, Europe, Canada, the Asia Pacific, and other international markets, the company is recognized for its integrated solutions that support the entire drug development cycle. It operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each tailored to meet the varied and complex needs of its clients. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to aiding its clients in the development of novel therapies and medicines through its vast expertise and comprehensive facilities.

Products and Services

Research Models and Services (RMS): This segment is integral to Charles River Laboratories' operations, producing and selling a wide variety of research rodents, including purpose-bred rats and mice. These are essential tools for researchers across the globe, enabling a myriad of scientific investigations and discoveries. Services offered within this segment also include:

  • Genetically Engineered Models and Services: Customization and production of genetically modified animals to meet specific research requirements.
  • Insourcing Solutions: Provision of skilled personnel and resources to manage and operate clients' laboratory animal facilities.
  • Research Animal Diagnostic Services: Comprehensive diagnostic services to ensure the health and genetic integrity of research models.

Discovery and Safety Assessment (DSA): A critical segment that supports early-stage drug discovery and safety assessment. The DSA segment delivers:

  • Early and in vivo Discovery Services: Identification and validation of novel targets, chemical compounds, and antibodies, alongside the delivery of preclinical drug and therapeutic candidates ready for safety assessment.
  • Safety Assessment Services: Extensive testing services including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics to ensure candidate drugs are safe for clinical trials.

Manufacturing Solutions (Manufacturing): This segment provides critical support in the quality control and testing of pharmaceuticals and consumer products. It encompasses:

  • In vitro Methods for Quality Control: Testing services for both sterile and non-sterile pharmaceuticals and consumer products, including specialized testing of biologics outsourced by pharmaceutical and biotechnology companies.
  • Contract Vivarium Operation Services: Operational support for biopharmaceutical clients’ vivarium facilities, ensuring the maintenance of high-quality standards in animal care and research.

Contact Information

Address: 251 Ballardvale Street
Phone: 781 222 6000